Informed Risk Assessment: Leveraging Preclinical Safety Intelligence to anticipate Clinical Adverse Events

Description

One of the biggest challenges the pharma industry continues to face today is the failure of drug candidates due to unexpected adverse reactions. Late-stage clinical attrition for safety reasons represents a high risk in terms of patient safety and cost. Early anticipation of safety issues enables informed decisions.

In this session we will present how OFF-X's analytic tools and curated data from a broad range of sources can help de-risk drug development.

Agenda:

• Challenges the pharma industry continues to face today 

• How the safety intelligence tool OFF-X can help de-risk drug development

  • Drug - Semagacestat

  • Target – BTK inhibitors

  • Target- 4-1BB activators

• Summary

• Q&A

Speaker: Kinsi Oberoi, Senior Solution Consultant​